Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 30, 2020

Researcher in India designs potential Covid-19 vaccine candidates

A researcher at University of Hyderabad (UoH) in India has designed potential Covid-19 vaccine candidates referred to as T cell epitopes.

A researcher at University of Hyderabad (UoH) in India has designed potential Covid-19 vaccine candidates referred to as T-cell epitopes.

The vaccine candidates are small coronaviral peptides, molecules used by cells to induce an immune response against the virus.

Computational tools cut the vaccine discovery process from years to days.

Dr Seema Mishra, a biochemistry department faculty member at the university’s School of Life Sciences, designed the candidates to act against all SARS-CoV-2 structural and non-structural proteins.

Furthermore, the candidates are capable of facilitating vaccination of the entire population.

Depending on how the candidates will be used by human cells against the virus, a ranked list has been generated.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

As there are no matches in the human protein pool, these coronavirus epitopes are expected to have no cross-reactivity to human cells, indicating promise that the immune response will be against viral proteins but not human proteins.

The university noted that the Covid-19 vaccine candidates are yet to be validated in-vitro. The research has been shared with the scientific community for experimental analysis.

Commenting on the Covid-19 vaccine candidates, Dr Mishra said: “Right now, best defence to prevent further nCoV infections is social distancing. Vaccination will take some time due to the need for further work on these candidate epitopes.

“We are hopeful that our computational findings will provide a cost-and-time-effective framework for rapid experimental trials towards an effective nCoV vaccine.”

Last month, Serum Institute of India announced that its Covid-19 vaccine candidate, being developed in collaboration with US-based Codagenix, entered pre-clinical/animal testing phase.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU